Shares issued under ESOP 2008 and MESOP 2018 plans following exercise of vested stock options, in compliance with SEBI disclosure norms
The collaboration underscores a broader industry shift toward hybrid research models that integrate computational biology with advanced experimental systems
Inspection outcome reinforces company's compliance track record and strengthens its ability to serve regulated markets including the United States
C-CAMP–Imperial College London partnership to boost biotech research, startup exchange, and translational innovation through a five-year collaboration
The Clinical Trial Application (CTA) approval clears the way for the company to launch trial locations in France and Romania
Drugmaker taps 1 million retail touchpoints, quick commerce and modern trade to expand ingredient-led skincare franchise
The acquisition adds VYKAT XR (diazoxide choline), the first FDA-approved therapy for hyperphagia in Prader-Willi syndrome (PWS), a rare genetic disorder, to Neurocrine’s portfolio
EB-003 is Enveric’s lead neuroplastogen, a 5-HT2A / 5-HT1B dual-acting compound designed to promote neuroplastic changes
Broadens downstream purification portfolio with next-generation Protein A chromatography for scalable manufacturing
Subscribe To Our Newsletter & Stay Updated
